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ABSTRACT: The zwitterionic Streptococcus pneumoniae serotype 1 polysaccharide (Sp1) is an important anchor point for our
immune system to act against streptococcal infections. Antibodies can recognize Sp1 saccharides, and it has been postulated that
Sp1 can elicit a T-cell-dependent immune reaction as it can be presented by MHC-II molecules. To unravel the molecular mode
of action of this unique polysaccharide we here describe the chemical synthesis of a set of Sp1 fragments, ranging from 3 to 12
monosaccharides in length. We outline a unique synthetic approach to overcome the major synthetic challenges associated with
the complex Sp1 structure and provide a stereoselective route of synthesis for the oligosaccharide backbone as well as a strategy
to introduce the carboxylic acid functions. Molecular dynamics (MD) simulations together with NMR spectroscopy studies
reveal that the oligosaccharides take up helical structures with the nona- and dodecasaccharide completing a full helical turn.
The 3D structure of the oligosaccharides coincides with the topology required for good interaction with anti-Sp1 antibodies,
which has been mapped in detail using STD-NMR. Our study has revealed the Sp1 nona- and dodecasaccharides as promising
synthetic antigens, displaying all (3D) structural elements required to mimic the natural polysaccharide and required to unravel
the molecular mode of action of these unique zwitterionic polysaccharides.
■ INTRODUCTION
Bacteria are surrounded by a thick layer of carbohydrates,
which is important for their fitness, virulence, and
pathogenicity.1 Lipopolysaccharides, exopolysaccharides, and
capsular polysaccharides (CPSs) protrude from the cell wall
encapsulating the bacterium to provide a thick layer of defense.
Forming the barrier between the bacteria and the extracellular
milieu, carbohydrates shape the interactions with their
environment, including the host immune system.2 They
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represent anchor points for carbohydrate binding receptors as
well as anticarbohydrate antibodies. Because they are
composed of unique repetitive structural motives, which are
strain/serotype or species specific, and they are built up from
monosaccharides that in most of the cases are not part of the
mammalian carbohydrate repertoire, they form attractive
antigens against which to direct vaccines. Generally, poly-
saccharides cannot be used as standalone vaccines, as they do
not elicit a T-cell response, required for affinity maturation
(class switching from IgM to IgG) and immunological
memory, especially in infants, children, and the elderly
population.1,3 Therefore, polysaccharides are covalently
conjugated to a carrier protein to recruit T-cell help and
mount an effective immune response. Although bacterial
polysaccharide vaccines are one of the biggest successes in
modern medicine, the mode of actionor lack thereofof
conjugate vaccines remains relatively ill-understood. It is
unclear how glycoconjugate vaccines are processed and
which parts of the conjugate are presented by antigen
presenting cells to T-cell receptors.3 Also, the effect of
carbohydrate loading on the efficacy of the conjugate vaccine
is unclear, and optimizing vaccine activity largely remains a
game of trial-and-error.4−6 It is often impossible to predict
what the optimal antigen is in a given polysaccharide, in terms
of chain length (the number of repeating units), substitution
pattern (e.g., degree of acetylation), and terminal residue (the
one that is in principle most exposed on the glycoconjugate).
The use of naturally sourced polysaccharide fragments in
combination with random conjugation chemistry makes
vaccine generation a relatively ill-defined process. Synthetic
chemistry can be used to generate well-defined epitopes to
establish immunological structure−activity relationships and
deliver tailor-made optimal antigens, which can be conjugated
in a site-selective manner, without altering the structure of the
antigen.4 Indeed, vaccines based on synthetic oligosaccharides
are being developed and have been brought to the market.7
The WHO estimates that every year around 2 million deaths
are caused by Streptococcus pneumoniae,8 and every 2 min, three
children die from pneumonia, making it the leading infectious
cause of child mortality globally. Normally, it does not cause
disease in healthy individuals, but in subjects with a weaker
immune system (young children, elderly, and immunocom-
promised patients), it may cause deadly infections, such as
pneumonia, septicemia, bacteremia, and meningitidis. S.
pneumoniae serotype 1 (ST1) presents a unique polysaccharide
(referred to as the Sp1 (poly)saccharide, see Figure 1), which
is composed of the rare monosaccharide 2-acetamido-4-amino-
2,4,6-trideoxy-D-galactose (D-AAT) and D-galacturonic acid
residues.9,10 Although Sp1 is a component in the currently
licensed vaccines, Prevnar 13, Synflorix (conjugated), and
Pneumovax 23 (nonconjugated), the exact active immuno-
logical epitope is unclear, and synthetic vaccines based on
small fragments of Sp1 are under active investigation to
improve the efficacy of anti-Sp1 glycoconjugate vaccines.11
The unique Sp1 polysaccharide harbors both positively (the C-
4-amino group of the D-AAT-residue) and negatively (on the
galacturonic acids) charged groups, leading to zwitterionic
motifs in the polysaccharide. The zwitterionic character of this
polysaccharide provides this structure with exceptional
immunological activity. In contrast to the vast majority of
polysaccharides (vide supra), zwitterionic polysaccharides
(ZPSs) are capable of inducing a T-cell-dependent immune
response. They can be taken up by antigen presenting cells
(APCs), processed, and presented in the context of major
histocompatibility (MHC-II) proteins to T-cells, leading to T-
cell activation.12−16 It has been proposed that the three-
dimensional structure of the Sp1 polysaccharide plays a
decisive role in positioning the positively and negatively
charged groups to interact with the presenting MHC-II
molecule.17 Likewise, the conformation of the polysaccharide
may play an important role in shaping the structure of Sp1
epitopes for binding to antibodies. To unravel the molecular
details behind the activation of both B-cells and T-cells by Sp1
saccharides, define optimal epitopes, and probe antibody and
MHC-II binding, well-defined synthetic fragments are
invaluable.18 Although some syntheses have appeared over
the years of the trisaccharide repeating unit, and a single route
of synthesis has been disclosed for the assembly of a Sp1
Figure 1. Structure of the Sp1 polysaccharide and the synthesis strategy to assemble structures 1−4.
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hexasaccharide, longer fragments encompassing multiple
repeating units have so far proven out of synthetic reach,
because of the tremendous synthetic challenge these molecules
pose.19−21
Scheme 1. (A) Synthesis of Building Blocks 10, 11, and 12, and (B) Assembly of Oligosaccharides 1−4a
aReagents and conditions: (a, i) Tf2O, pyridine, DCM; (ii) TBAN3, CH3CN; (iii) PhthNK, DMF, 30% (over three steps). (b, i) Ethylenediamine,
butanol, reflux; (ii) CbzCl, NaHCO3, THF/H2O, 69% (over two steps). (iii) LevOH, EDCI, DIPEA, DMAP, DCM, 91%. (c, i) NIS, TFA, DCM,
100%; (ii) N-phenyltrifluoroacetimidoyl chloride, K2CO3, acetone; 10, 79%; 11, 72%; 9, 89%. (d, i) TEMPO, BAIB, DCM/tBuOH/H2O, 4 °C;
(ii) BnBr, Cs2CO3, DMF, 67% (over two steps); (iii) LevOH, EDCI, DIPEA, DMAP, DCM, 97%. (e) Di-tert-butylsilyl
bis(trifluoromethanesulfonate), pyridine, 89%. (f) TfOH, DCM, −78 °C, 77% (α:β = 13:1). (g) N2H4·H2O, pyridine, AcOH, 0 °C to rt; 20,
89%; 22, 98%; 24, 97%; 26, 89%; 28, 91%. (h) TBSOTf, DCM, 0 °C; 9a, 85% (α:β = 13:1); 21, 82%; 23, 83%; 25, 80%; 27, 72%. (i, i) BOMCl,
DIPEA, TBAI, DCM, 89%. (ii) HF/Py, pyridine, THF, 0 °C to rt, 94%. (j, i) BOMCl, DIPEA, TBAI, DCM; (ii) PPh3, pyridine, H2O, THF, reflux,
7 h; (iii) Ac2O, pyridine; (iv) HF/Py, pyridine, THF, 0 °C to rt; 6, 69%; 7, 69%; 8, 77%. (k, i) TEMPO, BAIB, DCM/tBuOH/H2O, 4 °C; (ii)
Cs2CO3, BnBr, DMF, 0 °C to rt, 84%. (l) AcSH, pyridine, 66%. (m, i) NaOH, THF, MeOH; (ii) Na, NH3, THF, tBuOH, allylcarbinol or CH2
CHCH2CH2OPEG4OCH2CH2CHCH2; 1, 95%; 2, 39%; 3, 55%; 4, 47%. (n, i) TEMPO, BAIB, THF/tBuOH/DCE, 4 °C, then NaClO2,
iso-amylene, NaH2PO4, H2O, 63%. (o, i) TEMPO, BAIB, NaHCO3, EtOAc/tBuOH/H2O, 4 °C; (iii) Cs2CO3, BnBr, DMF, 0 °C to rt; 32, 45%;
33, 51%. (p, i) TEMPO, BAIB, NaHCO3, EtOAc/tBuOH/H2O, 4 °C; (iii) PhCHN2, DCM, Et2O, 49%.
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We now report on the development of an effective synthesis
route to assemble larger Sp1 oligosaccharides. The stereo-
selective strategy that we present has been used to generate
Sp1 oligosaccharides ranging in length from a trisaccharide
(one repeating unit) to a dodecasaccharide, encompassing four
repeating units. The strategy allows for the incorporation of an
alkene spacer at the “reducing” end of the saccharides, which
can be used for future conjugation purposes. Through detailed
structural studies, using molecular dynamics (MD) simulations
in combination with NMR spectroscopy we show that the
oligosaccharides take up a helical structure, with the ninemer
(3 repeating units) completing a full turn. We next show that
serum and antibody binding is length-dependent with the best
epitopes presenting at least one helical turn. Our study has
provided access to well-defined zwitterionic oligosaccharides
capable of mimicking the three-dimensional structure of the
natural polysaccharide. The availability of the fragments opens
the way to further structural studies, including those directed at
the presentation of the oligosaccharides by MHC-II molecules,
and enables the generation of synthetic vaccines, presenting
the structural epitopes as present in the natural polysaccharide.
■ RESULTS AND DISCUSSION
Synthesis. The structure of the Sp1 oligosaccharides
represents a multitude of challenges, which have to be
overcome in the development of an efficient route of synthesis,
accessing sufficient amounts of the target oligosaccharides.
First, the presence of rare D-AAT residues necessitates an
effective route of synthesis for this building block.22−24 Second
the cis-glycosidic linkages demand an effective stereoselective
glycosylation methodology.25−27 Especially when the growing
saccharide chains become larger, this represents a major
synthetic hurdle. Third, an effective solution has to be found to
introduce the carboxylic acid functionalities in the galacturonic
acids residues. Galacturonic acid building blocks generally
react poorly in glycosylation reactions, when used either as a
donor or as an acceptor,28,29 indicating that a postglycosyla-
tion−oxidation strategy, in which the glycan backbone is made
before the introduction of the carboxylic acids, is most
favorable. However, the late introduction of multiple carboxylic
acids also represents a major challenge,30 because every
alcohol-to-acid conversion requires two oxidation events, and
the polarity of the formed intermediates varies greatly. Finally,
a suitable conjugation handle has to be introduced, which can
be addressed chemoselectively in the presence of all other
functionalities (amines, carboxylic acids, and hydroxyl groups).
The synthetic strategy we developed to access trisaccharide
1, hexasaccharide 2, nonasaccharide 3, and dodecasaccharide 4
is depicted in Figure 1 and hinges on the use of the
trisaccharide building block 9. In our strategy we have
combined a preglycosylation−oxidation approach to introduce
one of the galacturonic acid residues in the repeating unit
building block, with a postglycosylation−oxidation approach to
introduce the second galacturonic acid moiety at the end of the
glycan assembly.31−33 This approach enables the use of a 4,6-
silylidene-protected galactose donor moiety, which represents
a highly reliable synthon for the stereoselective construction of
1,2-cis-galactosyl linkages34−36 and increases the donor’s
reactivity. At the same time, it minimizes the amount of
oxidative transformations that have to be executed at the end
of the assembly, because half of the galacturonic acids have
already been introduced at the building block level. We opted
for the incorporation of a but-3-en-1-ol spacer because the
double bond can be chemoselectively functionalized after
glycan assembly, for example, using thiol−ene click chem-
istry.37 The crucial trisaccharide building block 9 can be
assembled using the three monomeric synthons 10, 11, and 12.
Scheme 1 depicts the synthesis of the building blocks
(Scheme 1A) and the assembly of the oligosaccharides
(Scheme 1B). The AAT building block 10 was obtained
from D-mannose following a slight adaptation of Kulkarni’s
protocol (see the SI for full synthetic details).22 In 7 steps D-
mannose was converted into diol 13, which was transformed
into the bis-triflate to set the stage for the introduction of the
two masked amino groups. Regioselective substitution of the
C-2-triflate using tetrabutyl ammonium azide (TBAN3) and
consecutive replacement of the C-4-triflate for an N-
phthalimide functionality provided the AAT building block
14 in 30% yield.38 Removal of the C-3-O-acetate and phthaloyl
groups using ethylenediamine was followed by the introduc-
tion of the benzyloxycarbonyl group on the liberated C-4-
amine and levulinoylation of the C-3-alcohol. Thioglycoside 15
was transformed into the corresponding N-phenyltrifluoroace-
timidate 10 to allow for a chemoselective glycosylation toward
the trisaccharide building block (vide inf ra). The assembly of
the galacturonic acid building block 11 was achieved from
known building block 16,39 available from D-galactose in 6
steps. Regioselective oxidation and formation of the benzyl
ester was followed by levulinoylation of the free alcohol to
provide the fully protected galacturonic acid 17, which was
transformed into imidate donor 11. The silylidene-protected
galactose thioglycoside 12 was obtained from 2-O-benzyl
galactoside 18,40 generated from D-galactose in 6 steps. With
the three monomeric building blocks in hand the synthesis of
the pivotal trisaccharide building block was undertaken. First
galacturonic acid 11 and silylidene galactose acceptor 12 were
condensed to provide disaccharide 19. Considerable opti-
mization of the reaction conditions was required to install the
desired glycosidic linkage with good stereoselectivity (see the
SI for details), and ultimately dimer 19 was obtained in 77%
yield (α:β = 13:1) on the multigram scale. Delevulinoylation
then set the stage for the next chemoselective glycosylation
event, in which the desired trisaccharide 9a was obtained in
85% yield with good stereoselectivity (α:β = 13:1).41 The
thioglycoside 9a was next transformed into imidate building
block 9. Assembly of the oligosaccharides started with the
installation of the but-3-en-1-ol spacer. To this end donor 9
was condensed with allylcarbinol to give trisaccharide 21 in
82% as a single anomer, indicating the apt glycosylation
properties of the donor building block. Delevulinoylation was
followed by the next glycosylation event to give hexasaccharide
23 in 80% again as a single diastereoisomer.42 A similar round
of deprotection and glycosylation reactions then provided the
nonasaccharide 25 (80%, α-only) and dodecasaccharide 27
(72%, α-only), showing the effectiveness of the silylidene
donor and glycosylation strategy devised. To generate the
target compounds 1−4 we then turned to the deprotection and
functionalization chemistry. First, the free alcohol in trimer 22
was masked with a benzyloxymethyl ether, as it has previously
been observed that deprotection of the C-3-OH of the AAT
building block under basic conditions can lead to formation of
the cyclic C3-O-C-4-N-carbamate.20,21 Next the silylidene ketal
was removed yielding diol 29, of which the primary alcohol
was regioselectively oxidized using the TEMPO/BAIB reagent
combination to give, after formation of the benzyl ester to ease
the purification, trisaccharide 30. Global deprotection of this
ACS Central Science Research Article
DOI: 10.1021/acscentsci.9b00454
ACS Cent. Sci. 2019, 5, 1407−1416
1410
trimer was affected by transformation of the azide into the
corresponding acetamide 31 using thioacetic acid,43,44 after
which the benzyl esters were saponified, and the remaining
benzyl ethers, benzyloxycarbamate and benzyloxymethyl ether
were removed using a dissolving metal reduction.21,45 This last
step proved challenging and required careful optimization.
Addition of tert-butanol to the Birch reaction (using sodium in
ammonia) was necessary to prevent removal of the acetyl from
the AAT amino group, and addition of allylcarbinol as a “decoy
substrate” diminished undesired reduction of the spacer double
bond. Trisaccharide 1 was eventually obtained in 95% yield.
Next, the transformation of the larger oligosaccharides into
target compounds 2, 3, and 4 was undertaken. First the
levulinoyl group in the oligomers was replaced by a BOM ether
as described above, and subsequently the azides were
transformed into the acetamides. Whereas the use of thioacetic
acid proved effective for the trisaccharide, it did not work well
for the simultaneous reductions on the longer fragments.
Therefore, we switched to a Staudinger reduction/acetylation
sequence.46,47 After desilylation, the oxidation precursors 6, 7,
and 8 were obtained. Although the TEMPO/BAIB oxidation
was effective in the synthesis of trisaccharide 1, it failed in the
assembly of the larger oligosaccharides, underscoring the
difficulty in effecting multiple simultaneous oxidation reac-
tions. We therefore explored the use of the two-step one-pot
TEMPO/BAIB Pinnick oxidation protocol we recently
introduced for reluctant substrates.36 Following this two-step
oxidation sequence, the hexamer 6 was successfully trans-
formed into the dicarboxylic acid (63% yield), which was
benzylated to give 32. Unfortunately, the oxidation of the three
alcohols in nonamer 7 could not be accomplished using the
TEMPO/BAIB Pinnick reaction sequence, and a complex
Figure 2. Structure of the zwitterionic oligosaccharides 1−4. (A) NOESY spectrum of trimer 1 (500 ms mixing time) acquired at 800 MHz. Key
inter-residue NOEs are indicated. (B) MD conformational analysis of 1 with the superimposition of 10 frames and plots of Φ/Ψ values explored
along the 100 ns MD trajectory. The points are colored as a function of the population density. (C) Representative geometries of hexasaccharide 2,
nonasaccharide 3, and dodecasaccharide 4 from the 500 ns MD simulations. The nonamer and dodecasaccharide make a full helical turn,
comprising 8 monosaccharide residues and spanning ca. 25 Å. Both the major and minor syn(−)-Ψ and syn(+)-Ψ geometries for the GalAα1−
3GalA moieties contribute to the helical geometry in the long oligosaccharides.
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Figure 3. Binding studies of the synthetic oligosaccharides with the anti-Sp1 antibodies. (A) Competitive ELISA for antide-O-Ac Sp1 serum. (B)
Competitive ELISA for the human pneumococcal reference serum 007sp. (C) STD and off-resonance NMR spectra for the interaction between
anti-Sp1 IgG2a mAb and trimer 1. (D) Structure of 1−4 where protons with the highest STD response are highlighted to delineate the binding
epitope. The relative STD for overlapped protons was equally distributed in the structures of 3 and 4. (E) STD and off-resonance NMR spectra for
mixtures mAb:2, mAb:3, and mAb:4. The relative STD responses of H4 and NHAc protons of terminal and inner core AAT residues for hexamer
2, nonamer 3, and dodecamer 4 are highlighted. (F) Representative 3D structure of the dodecasaccharide 4, in which the STDs are indicated by
colors.
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product mixture was obtained. It has previously been shown
that efficiency of TEMPO mediated oxidations can be
significantly improved under basic conditions. Presumably,
the basic conditions48 accelerate the formation of the hydrate
from the intermediately formed aldehyde, enhancing the rate
of the oxidation to the carboxylate. To test whether basic
conditions could improve the challenging oxidations reactions
required here, the hexasaccharide 6 was subjected to TEMPO/
BAIB treatment in the presence of NaHCO3. Under these
conditions the dicarboxylic acid was obtained in a similar yield
(67%) in comparison to the TEMPO/BAIB Pinnick sequence.
Importantly nonasaccharide 7 could now be transformed into
the tricarboxylic acid, and after benzylation, nonamer 33 was
obtained in 51% yield (over two steps). Application of this
protocol to the most complex substrate, dodecamer 8,
delivered, after benzylation using benzyl bromide and
K2CO3, the octa-benzyl ester 34 in only 19% yield over the
two steps. To further improve on the protocol, milder and
more efficient benzylation conditions, using phenyldiazo-
methane,49,50 were used. This way, dodecasaccharide 34 was
obtained in 49% over the two steps. To complete the syntheses
of hexamer 2, nonamer 3, and dodecamer 4, the
oligosaccharides were deprotected by saponification of the
benzyl esters, and global reductive debenzylation provided the
target oligomers in 39% (for 2), 55% (for 3), and 47% (for 4)
yield, respectively.
Structure. It has been proposed that the three-dimensional
structure of the Sp1 polysaccharide is important for its T-cell
activating activity.17,51,52 Using NMR experiments combined
with molecular dynamics (MD) calculations, it was proposed
that the natural Sp1 polysaccharide takes up a right-handed
helical structure with 8 monosaccharides per turn.17 To probe
whether the relatively short fragments 1−4 are capable of
adopting a secondary structure we took a similar approach to
establish the three-dimensional structure of the oligosacchar-
ides. The NOESY spectrum of 1 showed key unequivocal
inter-residue cross-peaks, which allowed defining the sugar
conformation (Figure 2A). In particular, NOEs for H1AAT−
H4GalA2, H1GalA2−H3GalA1, and H1GalA2−H4GalA1
proton pairs defined exo-syn-Φ/syn-Ψ conformations around
both glycosidic linkages. Fittingly, the 100 ns MD simulation
predicted exo-syn-Φ/syn-Ψ conformations for both linkages
(Figure 2B). The Φ and Ψ dihedral angles for the AATα1−
4GalA linkage remained fairly stable along the trajectory and
mainly populated the exo-syn-Φ/syn(+)-Ψ conformation. In
comparison, the GalAα1−3GalA linkage is slightly more
flexible with transitions between syn(−)-Ψ and syn(+)-Ψ
conformers occurring along the entire simulation. Although the
conformational flexibility around Ψ is not fully discernible by
NOESY experiments, NOE-estimated distances matched well
with the average distances derived from the MD simulation of
sugar 1 and pointed to the presence of syn(−)-Ψ and syn(+)-Ψ
conformers (see Table S3). Thus, the MD simulation provided
a proper model of the conformational features of 1. Similarly,
NMR analysis was combined with MD simulations to analyze
the conformational features of the longer oligosaccharides 2−
4. It is noteworthy that 1H and 13C NMR signals of both
central units (B and C) of dodecasaccharide 4 became
indistinguishable. This is the case for the natural saccharide,
where only one set of resonances is observed for the same
residue of different units. NOESY experiments are fully
compatible with the exo-syn-Φ/syn-Ψ conformations around
AATα1−4GalA, GalAα1−3GalA, and GalAα1−3AAT glyco-
sidic linkages in all the units, and the 500 ns MD simulation
performed for 2−4 supported these results (see Tables S4−
S6). As for 1, the long oligosaccharides displayed exosyn-Φ/
syn(+)-Ψ, exo-syn-Φ/syn(±)-Ψ, and exo-syn-Φ/syn(−)-Ψ
conformations for the AATα1−4GalA, GalAα1−3GalA, and
GalAα1−3AAT linkages, respectively. Thus, although the
structural complexity increases by the addition of repeating
units, the conformational flexibility around each glycosidic
linkage remains essentially unaltered, with no correlation
between remote residues. The analysis of the global structure
of 3 and 4 revealed that they display a well-defined extended
conformation (Figure 2C). Indeed, MD simulations predicted
a large radius of gyration (RoG) and distances between both
ends that extended beyond 30 and 40 Å, respectively (see
Figure S3B). In particular, both sugars take up a right-handed
helical structure with eight residues per turn, 5.04 Å of average
separation between residues, and a pitch of ca. 25 Å (Figure 2),
in line with the structure proposed for the Sp1 polysaccharide.
Furthermore, and as also described for the natural poly-
saccharide, the positive and negative charges of the synthetic
molecules are uniformly distributed, with the amino group of
each AAT residue and the carboxyl groups of the previous and
following GalA residues pointing at opposite sides of the helix
(Figure S5).
Antibody Recognition. To probe binding of the synthetic
oligosaccharides to antibodies directed at the capsular
polysaccharide and establish how the length of the oligomers
affects binding, inhibition ELISA experiments were performed.
To generate serum against the de-O-acetylated natural
polysaccharide (de-O-Ac Sp1) we conjugated the de-O-Ac
Sp1 polysaccharide to tetanus toxoid, by periodate oxidation of
the polysaccharide and a subsequent reductive amination
conjugation step. Balb/c mice were immunized with the
conjugate adsorbed on aluminum phosphate. Three immuniza-
tions were performed at 14 day intervals, and blood was
collected 7 days postimmunization. ELISA wells were coated
with the de-O-Ac Sp1 polysaccharide, and binding of the
polyclonal antide-O-Ac-Sp1 serum was investigated in the
presence of oligosaccharides 1−4. Native and de-O-Ac Sp1
polysaccharides were used as positive controls, and the
structurally nonrelated S. pneumoniae capsular polysaccharide
19F was employed as a negative control inhibitor. As depicted
in Figure 3A, the shortest oligosaccharide 1 did not inhibit
antibody binding to the surface bound polysaccharide, while
the longer oligosaccharides were capable of binding the
antibodies in the serum. A clear length dependence was
observed for the longer oligosaccharides, with the longest
fragments 3 and 4 showing best binding. Notably, there was
relatively little difference between the nona- and dodeca-
saccharide 3 and 4, and effective binding coincides with the
length of the oligomers which can generate a full helical turn.
Next, we probed the human pneumococcal serum 007sp,53
raised against the 23-valent S. pneumoniae vaccine Pneumovax
II, for binding to oligosaccharides 2−4 (Figure 3B). To this
end ELISA wells were coated with the native Sp1
polysaccharide, and binding of serum antibodies was
investigated in the presence of oligosaccharide inhibitors. As
shown in Figure 3B, also here a specific length-dependent
inhibition was observed with the fragments completing the full
helical turn, binding significantly better than the shorter
fragment.
To explore binding of the synthetic compounds in more
detail, the interaction of the synthetic Sp1 oligomers 1−4 with
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an anti-Sp1 IgG2a monoclonal antibody54 was evaluated by
STD-NMR experiments.55 First, we analyzed the binding with
the smallest glycan, trimer 1. STD experiments for the 1:200
mixture of mAb:1 provided very clear STD signals for H3−H5
of GalA2 and H1−H2 of GalA1 residues. These results suggest
that both GalA are involved in the binding, with H3−H5 and
H1−H2 of GalA2 and GalA1, respectively, pointing toward the
protein surface, whereas the AAT moiety seems to be solvent
exposed (see Figure 3C,D). In addition, trNOESY experiments
for a 1:200 mixture of anti-Sp1 mAb:trimer 1 were applied to
identify, if any, changes on the conformation of the sugar in the
free and bound states. The inspection of NOE cross-peaks
indicated that the bound conformation is very similar to the
most populated conformation in solution. In particular, NOEs
for H1AAT−H4GalA2, H1GalA2−H3GalA1, and H1GalA2−
H4GalA1 proton pairs observed for the free sugar at 800 MHz
and defining the exo-syn-Φ/syn-Ψ conformation around both
glycosidic linkages are also present in the bound conformation
(see Figure S10).56 Next, the interaction of hexamer 2 with the
anti-Sp1 mAb was analyzed (see Figure 3D and Figure S12).
As for trimer 1, H3−H5 protons of the GalA2 of unit A
showed the strongest STD effect, and important signals were
also observed for H1−H2 protons of GalA1 (unit A). Thus,
both 1 and 2 bind comparably to the antibody, where the
GalA2 moiety seems essential for the recognition. In addition,
the H3−H5 protons of GalA2 and H1−H2, H5 of GalA1 of
unit B showed significant STD responses, indicating that these
residues are also involved in the binding event. In contrast, the
STD effect of AAT residues was lower, especially that of unit B
at the “nonreducing” end, indicating that this residue is more
solvent exposed. These results indicate that both repeating
units A and B in 2 take part in the interaction with the
antibody and suggest an extended binding epitope for hexamer
2. Notably, most of the protons with the highest STD
intensities are located at the same molecule face that would be
oriented toward the antibody (see Figure S12). Analogous
STD experiments were performed for compounds 3 and 4 and
provided clear evidence of the interaction. However, because
of the high level of peak overlapping in the 1H-STD spectra,
detailed analysis of the binding epitope was hampered (see
Figures S13 and S14). Overall, the STD epitope determined
for nonamer 3 resembles that depicted above for hexamer 2
(Figure 3D). Several nonoverlapped protons of residues of
units A, B, and C showed significant STD responses, strongly
suggesting the presence of an extended binding epitope. It is
noteworthy that the most intense STD signals were found for
protons of the GalA2 residues, especially for those of the inner
units A and B. In line with the binding of the trisaccharide 1
and hexasaccharide 2, the protons of the AAT residue at the
terminal end of the sugar (unit C) received the lowest
saturation, indicating that this residue is again more exposed to
the solvent. Finally, the STD experiments for a 1:30 mixture of
mAb:4 indicated that dodecamer 4 binds in a similar fashion to
the antibody. Protons of the AAT moiety at the terminal end
(unit D) showed the lowest saturation, whereas important
STD was detected for protons belonging to several residues of
units A−D, indicating an extended epitope (Figure 3D). It is
noteworthy that when STD effects for compounds 2−4 are
compared, insight is gained on the length of the antigen
binding epitope. The STD response of protons of the terminal
AAT and those of inner AAT residues differed, as a function of
the length of the saccharides, showing a different involvement
of the terminal AAT in the binding of each ligand (see Figure
3E). The STD responses of H4 and NHAc protons of the
terminal and inner core AAT residues are fairly similar for
hexamer 2. This indicates that both residues are equally close
to the protein surface. In contrast, the STD response of these
residues became considerably different for nonamer 3, where
the terminal AAT, with a lower STD effect, is more exposed to
the solvent. Similarly, dodecamer 4 showed different responses
for the terminal and internal AAT residues. Together, these
data indicated that the antigen binding site of the antibody is
able to accommodate two repeating units as in compound 2,
but not entirely the third one as in compound 3, where the
terminal AAT residue is further away from the protein surface.
These results thus point to a minimal binding epitope of 7−8
residues length, coinciding with the number of residues per
turn of the helix displayed by the longer and native Sp1
oligosaccharides. Therefore, all results suggest a groovelike
antigen binding site topology57 for the antibody capable of
binding a fragment of polysaccharide encompassing a full
helical turn.58−60
■ CONCLUSION
This study has delivered a strategy for the assembly of large
synthetic zwitterionic Sp1 oligosaccharides. The combination
of a preglycosylation−oxidation strategy to introduce one of
the carboxylate groups in the repeating unit with a
postglycosylation−oxidation strategy to enable the fully
stereoselective union of the trimer repeats has proven effective
to assemble these complex oligosaccharides. Novel conditions
have been employed to simultaneously introduce multiple
carboxylates in a complex oligosaccharide through a modified
TEMPO/BAIB oxidation. The devised conditions for this
transformation can find further application in the assembly of
complex oligosaccharide targets, such as heparins and other
anionic bacterial capsular polysaccharides. Detailed structural
studies revealed the synthetic Sp1 fragments to take up helical
structures with the ninemer completing a full turn. The Sp1
oligosaccharide helices closely match the structures of the Sp1
polysaccharide placing the positively charged amino groups
and negatively charged carboxylates of a repeating unit on
different sides of the helix (see Figure 2C and Figure S5). It is
shown that the binding of the oligosaccharides to both human
and murine antibodies is length-dependent with the best
binders being those oligosaccharides that can structurally
complete a full helical turn, i.e., ninemer 3 and dodeca-
saccharide 4. STD-NMR studies have confirmed the size of the
best “minimal epitope” to encompass 7−8 monosaccharide
residues and suggest a groove-type recognition mode where
almost three repeating units of the oligo- or polysaccharides
can be accommodated in the antibody binding site. It was
recently reported that a structure as small as a single repeating
unit may be used in a synthetic conjugate vaccine targeting S.
pneumoniae serotype 1.11 Although this conjugate could be
used to raise opsonophagocytic anti-Sp1 antibodies in rabbits,
the use of larger Sp1 fragments may trigger higher IgG titers
having a better avidity for the Sp1 capsule. Higher IgG titers
and more avid IgG are a key concept to remove
nasopharyngeal carriage and decrease the transmission of S.
pneumoniae. Our study reveals nonasaccharide 3 to be a very
attractive candidate for the generation of an anti-Sp1 vaccine
modality, and to this end the alkene conjugation handle may
be exploited to hook up the saccharide to a carrier protein. The
availability of the helical oligosaccharides will also enable
structural studies to unravel the binding of these saccharides to
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MHC-II molecules. It has been proposed that zwitterionic
polysaccharides and teichoic acids can bind to these molecules
allowing their presentation to T-cell receptors, triggering a T-
cell response. The well-defined structures disclosed here will be
instrumental in unravelling the enigmatic immunological
behavior of these unique polysaccharides.
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scale synthesis of an orthogonally protected 2-acetamido-4-amino-
2,4,6-trideoxy-D-galactose (AAT) building block. Carbohydr. Res.
2012, 356, 282−287.
(25) Demchencko, A. V., Ed. Handbook of chemical glycosylation:
Advances in stereoselectivity and therapeutic relevance; Wiley-VCH,
2008.
(26) Bennet, C. S., Ed. Selective glycosylations: Synthetic methods and
catalysts; Wiley-VCH, 2017.
ACS Central Science Research Article
DOI: 10.1021/acscentsci.9b00454
ACS Cent. Sci. 2019, 5, 1407−1416
1415
(27) Nigudkar, S. S.; Demchenko, A. V. Stereocontrolled 1,2-cis-
glycosylation as the driving force of progress in synthetic carbohydrate
chemistry. Chem. Sci. 2015, 6, 2687−2704.
(28) Van der Vorm, S.; Van Hengst, J. M. A.; Bakker, M.; Overkleeft,
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